With a one year PEG ratio of 635.46, Celldex Therapeutics Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.12% of US stocks.
With a price/sales ratio of 174.41, Celldex Therapeutics Inc has a higher such ratio than 97.88% of stocks in our set.
The volatility of Celldex Therapeutics Inc's share price is greater than that of 96.95% US stocks with at least 200 days of trading history.
If you're looking for stocks that are quantitatively similar to Celldex Therapeutics Inc, a group of peers worth examining would be PULM, EVGN, CBIO, ARCT, and PIRS.
Celldex Therapeutics is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company was founded in 2004 and is based in Hampton, New Jersey.
Celldex Therapeutics (CLDX) is a development-stage pharmaceutical company. It was once a high-flyer, before its lead candidate failed a Phase 3 trial in 2015. More recently, before the CDX-0159 news was announced in June, it was selling at about $3.00 per share. On September 30, 2020, Celldex closed at $14.83...
Tricida suffers setback on Veverimer front Tricida Inc. (TCDA) reported that the FDA has given a Complete Response Letter to the company for its application pertaining to Veverimer. The New Drug Application for the drug candidate was being reviewed under the Accelerated Approval Program. Tricida is looking to request a...
Avisol Capital Partners on Seeking Alpha | August 26, 2020